Nitromemantine (YQW-36) is a derivative of memantine developed in 2006 for the treatment of Alzheimer’s disease. It has been shown to reduce excitotoxicity mediated by over-activation of the glutamatergic system by blocking NMDA-type glutamate receptors.
This page contains content from the copyrighted Wikipedia article "Nitromemantine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
